Management Team

Lee Roy Morgan

MD, PhD, CEO

Education

  • Tulane University, New Orleans, LA B.S. Chemistry 1958
  • Tulane University, New Orleans, LA M.S. Chemistry 1959
  • Tulane University, New Orleans, LA Ph.D. Chemistry/Pharmacology 1960
  • Imperial College of Science, London Post-Doc Chemistry 1960
  • Louisiana State Univ. School of Medicine, New Orleans, LA M.D. Medicine 1971
  • Intern –Touro Infirmary, New Orleans, LA 1971-2 Medicine (Rotating)
  • Clinical Pharmacology – fellow 1972-4 Clin Pharmacology

Positions and Honors

  • LA State Univ. Med. Center, New Orleans, LA - Professor/Chairman of Pharmacology (Ret.)
  • 1961-1986 and LSUMC Private medical practice plan/clinic – Oncology/Pharmacology (1972 –1986)
  • University of New Orleans, Adjunct Research Professor, Chemistry, 1987 - present
  • Graduate Faculty, 2008 - present.
  • DEKK-TEC, INC., New Orleans, LA, CEO/Director of Research, 1983 - present
  • DEKK-TEC Manufacturing Facility, New Orleans, LA Director – 2009 - present
  • Private Medical Practice – Medical Oncology 1986 – present
  • Tibbetts Award – National Small Business Agency Research Award in Oncology – 2000
  • M.D. Anderson Cancer Hospital, Houston, TX - Visiting Scientist/staff, Molecular Pathology, 2007 – present
  • AAAS Fellow – Amer. Assoc. Advancement of Science – elected 2009

Selected peer-reviewed publications (190)

  1. Adams, D.J., Waud, W.R., Wani, M.C., Manikumar, G., Flowers, J.L., Driscoll, T. A., Morgan, L.R.
    BACPTDP: A Water-Soluble Camptothecin Pro-Drug with Enhanced Activity in Hypoxic/Acidic Tumors.
    Cancer Chemotherapy Pharmacology, Published on line – March, 2010.
  2. Schlecht, H.P., Nguyen, B., Dezube, B.J., Nagle, D., Panther, L.A. Silverman, M., Goldstone, S. E., Morgan, L.R.
    4,4’-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in the treatment of perianal high grade squamous intraepithelial lesions: A proof of concept study.
    HIV Clinical Trials, The 25th International Papillomavirus Conf, Sweden, May, 2009.
  3. Morgan, L.R., Struck, R.F., Rodgers, A.H., Jursic, B.S. Waud, W. R. Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemotherapy Pharmacology, 64, 829-835, 2009.
  4. Morgan, L.R., Struck, R.F., Rodgers, A.H. , Bastian, G., Jursic, B. S., Papaginnis, C., Waud, W. Intracerebral metabolism and pharmacokinetics of 4-demethyl-4-cholesteryloxy- ACCP carbonylpenclomedine (DM-CHOC-PEN). Proc. Amer. Assoc. Res., 49: abst. 3745, 2008.
  5. Morgan, L.R., Struck, R.F., Rodgers, A.H., and Serota, D.G. Preclinical Pharmacology and Toxicity of 4-Demethylcholestryloxylcarbonylpenclomedine (DM-CHOC-PEN). Proc. Amer. Assoc. Res., 48: abst. 5614, 2007.
  6. R.P. Gale, A. van Vugt, L. Rosen, R.F. Struck, L.R. Morgan, P. LoRusso. ZIO-201: A Phase 1 Study of Isophosphoramide Mustard (IPM-lysine) in Advanced Cancers. ASCO, 24, 524, 2006.
  7. Eilender, D., LoRusso, P., Thomas, L., McCormick, C., Rodgers, A.H., Hooper, C.L., Tornyos, K. Krementz, E.T., Parker, S., and Morgan, L.R. 4,4’-Dihydroxybenzophenone-2,4-dinitro-phenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemotherapy Pharmacology, 52, 120-129, 2005.
  8. Germain, R., Bastian, G., Serota, D., Struck, R.F., Morgan, L.R. Isophosphoramide mustard (IPM): Preclinical pharmacology and toxicology in rodents, dogs and primates. Cancer Chemotherapy Pharmacology, 51, 1204-1212, 2004.
  9. Morgan, L.R., Thangaraj, K., LeBlanc, B., Hooper, C. H. Design, synthesis and anticancer properties of 4,4’-dihydroxybenzophenone-2, 4-dinitrophenylhydrazone (A-007) and analogs, J. Med. Chem. 46, 4552-44563, 2003.
  10. Struck, R.F., Tiwari, A., Friedman, H.S., Keir, S., Morgan, L.R. and Waud, W. Aryl derivatives of demethylpenclomedine, an antitumor, non-neurotoxic metabolite of penclomedine. Cancer Chemother. Pharmacol., 48, 47-52, 2001.
  11. Morgan, L.R. Rodgers, A.H., Hooper. C.L., Ratterree, M., Soike, K., Serota, D., Bies, R., and Schwartz, S.L. Comparative dermal pharmacology and toxicology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenyhydrazone (A-007) in rodents and primates. IN VIVO, 15, 501-507, 2001.
  12. Subramanian, S., Rodgers, A.H., Soike, K., Ratterree, M. and Morgan, L.R. Relative bioavailability and pharmacokinetics of 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone (A-007) in rats and monkeys, Journal of Experimental Therapeutics and Oncology, 1, 62-65, 1996.
  13. Morgan, L.R., Krementz, E.T., Fan, S.W. and Fan, D. Adoptive immunotherapy for advanced renal cell cancer using PHA-stimulated autologous lymphocytes. Anticancer Res. 13, 1763-68, 1993.
  14. Morgan, L.R., Hooper, C.L., Fan, D., Sartin, B.W. and Harrison, T.J. Toxicology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007). European J. Pharmacology, 183, 2449-2510, 1990.
  15. Stewart, D.J., Morgan, L.R., Verma, S., Maroun,J.A., Thibault, H. Pharmacology, relative bioavailablity and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study. Invest. New Drugs 13, 99-107, 1995.
  16. Morgan, L. R., Posey, L.E., Rainey, J., Ryan, D. Vial, R., Hull, E.W. Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat. Rep. 65, 693-695, 1981.
  17. Morgan, L.R., Southerland, C., Krementz, E.T., Schein, P.S., Woolley, D. A Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat. Rep. 60, 1437-1443, 1976.
  18. Boyer, J.H., Mack, C. H, Goebel, N., Morgan, L.R. Reactions of Sodium Phenylacetylide and Sodium Alkoxides with Tosyl and Mesyl Azides. J.Org, Chem. 23, 1051-1053, 1958.

Andrew H. Rodgers

PhD, Director of Regulatory Affairs

Education/Training

  • B.A. University of Keele, England 1978 – 1982
  • Ph. D. University of New Orleans, New Orleans, Louisiana 1986 – 1990

Field of Study

  • Analytical Chemist

Positions and Honors

  • Witco Chemicals, Taft, LA. Environment Supervisor, 1990 – 1995
  • DEKK-TEC, INC., Dir. Regulatory Affairs & Analytical Research, 1990 – present
  • Imperial Division of Carboline, New Orleans, LA, Process and Development Chemist 1984 – 1985

Selected peer-reviewed publications (in chronological order.)

  1. Morgan, L.R., Rodgers, A.H., Hooper, C.L., Harrison, T. and Sartin, B. 4,4’-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): Comparative anogenital pharmacology and toxicology in rodents and non-human primates. Cancer Chemotherapy Pharmacology, 54, Accepted, 2007.
  2. Morgan, L.R., Struck, R.F., Rodgers, A.H., and Serota, D.G. Preclinical Pharmacology and Toxicity of 4-Demethylcholestryloxylcarbonylpenclomedine (DM-CHOC-PEN). Proc. Amer. Assoc. Res., 48: abst. 5614, 2007.
  3. Eilender, D., LoRusso, P., Thomas, L., McCormick, C., Rodgers, A.H., Hooper, C.L., Tornyos, K. Krementz, E.T., Parker, S., and Morgan, L.R. 4,4’-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemotherapy Pharmacology, 52, 120-129, 2005.
  4. Morgan, L.R., Thangaraj, K., Rodgers, A.H., LeBlanc, B., Hooper, C. H. Design, synthesis and anticancer properties of 4,4’-dihydroxybenzophenone-2, 4-dinitrophenylhydrazone (A-007) and analogs, J. Med. Chem. 46, 4552-44563, 2003.
  5. Morgan, L.R., Rodgers, A.H., Hooper, C. L. and Jursic, B.S. Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogs and their ability to interact with lymphoendothelialcell surface markers. Bioorg. Med. Chem. Ltts., 12, 3407-3411, 2002.
  6. Morgan, L.R., Rodgers, A.H., LeBlanc, B.W., Boue’, S.M., Cole, R., and Jursic, B.S. Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) 3,7-diaminophenothiazin-5-ium double salts. Bioorg. Med. Chem. Ltts., 11, 2193-2195, 2001.
  7. Morgan, L.R. Rodgers, A.H., Hooper. C.L., Ratterree, M., Soike, K., Serota, D., Bies, R., and Schwartz, S.L Comparative dermal pharmacology and toxicology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rodents and primates. IN VIVO, 15, 501-507, 2001.
  8. Morgan, L.R., Rodgers, A.H., Fan, D., Soike, K., Ratterree, M., Sartin, B.W., and Harrison, T.J. comparative preclinical toxicology and pharmacology of 4,4'-dihydroxybenzophenone-2,4- dinitrophenylhydrazone (A-007) in vitro and in rodents and primates. IN VIVO, 11:29-38, 1997.
  9. Subramanian, S., Rodgers, A.H., Soike, K., Ratterree, M. and Morgan, L.R. Relative bioavailability and pharmacokinetics of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rats and monkeys, Journal of Experimental Therapeutics and Oncology, 1, 62-65, 1996.
  10. Rodgers, A.H., S. Subramanian, and Morgan, L.R. High performance liquid chromatography determination of A-007 in plasma. Jourrnal of Chromatography B, 670, 365-368, 1995.
  11. Rodgers, A.H., and Khaldei, M.G. Influence of pH retention in micellar liquid chromatography: consequences of micellar induced shifts of ionization constants. Analytical Chemistry, 66, 327-334, 1994.
  12. Rodgers, A.H., Strasters, J.K., and Khaldei, M.G. Simultaneous optimization of pH and micelle concentration in micellar liquid chromatography., J. of Chromatography, 636, 203-212, 1993.
  13. Khaledi, M.G., Strasters, J.K., Rodgers, A.H. and Breyer, E.D. Simultaneous enhancement of separational selectivity and solvent strength in reversed-phase liquid chromatography using micelles in hydro-organic solvents. Analytical Chemistry, 62, 130-136 1990.
  14. Khaledi, M.G. and Rodgers, A.H. Micellar mediated shifts of ionization constants of amino acids and peptides. Analytica Chimica Acta, 239, 121-128, 1990.
  15. Strasters, J.K., Rodgers, A.H., and Khaldei, M.G. Separation of ionizable solutes by micellar electrokinetic capillary chromatography (MECC) and micellar liquid chromatography (MLC). Consequences of micellar mediated shifts of ionization constants. 14th International Symposium on Liquid Chromatography; Boston, 1990.
  16. Strasters, J.K., Breyer, E.D., Rodgers, A.H., and Khaldei, M.G. Simultaneous optimization of variables influencing selectivity and elution strength in micellar liquid chromatography. Journal of Chromatography, 511, 17-33, 1990.
  17. Rodgers, A.H. and Khaldei, M.G. Amino acid resolution via MLC. Pittsburgh Conference and Exposition; New Orleans, LA. 1988.

Lisa Stokes-Hasten

BSRN, Certified oncology nurse

Edmund N. Benes

BS, Cell Technology/Research Technologist

Education

  • Louisiana State University, Baton Rouge, LA, B.S. Microbiology, 1958-62
Professional Experience
  • 1962-1972 – Research Specialist – Transplant Surgery, Tulane University Medical Center, New Orleans, LA
  • 1972-1979 – Research Specialist – Tissue Culture Lab, Charity Hospital of Louisiana, New Orleans, LA
  • 1980-1985 – Research Specialist – Dept. of Immunology, Tulane University Medical Center, New Orleans, LA
  • 1985-1990 – Senior Research Associate – Immunocytology, Imreg Inc, New Orleans, LA
  • 1995-1997 – Transplant Technologist – A. J. Lama, MD, New Orleans, LA
  • 1997-2002 – Facility Coordinator, Astrobiology Lab, Tulane Medical Center, New Orleans, LA
  • 2002-present – Research Technologist – DEKK-TEC, Inc., New Orleans, LA

Publications

  • Hammond TG, Benes E, O’Reilly KC , Wolf DA, Linnehan RM, Taher A, Kaysen JH, Allen PL, Goodwin TJ. Mechanical culture conditions effect gene expression: gravity-induced changes on the space shuttle. Physiol Genomics. 2000 Sep 8;3(3): 163-73.
  • Wang XC, Saban R, Kaysen JH, Saban MR, Allen PL, Benes EN, Hammond TG. Nuclear factor kappa B mediates lipopolysaccharide-induced inflammation in the urinary bladder. J Urol. 2000 Mar;163(3):993-8.
  • Hammond TG, Lewis FC, Goodwin TJ, Linnehan RM, Wolf DA, Hire KP, Campbell WC, Benes E, O’Reilly KC, Globus RK, Kaysen JH. Gene expression in space. Nat Med. 1999 Apr;5(4):359.
  • Thangaraj K, Morgan LR, Benes E, Jursic BS, Fan D. Aryl-2, 4-dinitrophenylhydrazone anticancer activities in vitro against human cancer cells. Breast cancer Res. and Treat. 2-2,7 150, 1993.
  • Morgan LK, Benes E, Fan D. Use of 4, 4-Duhydroxybenzo-phenome-2, 4-dinitrophenvlhydrazone (A-007) as an indicator for Systematic Cancer Therapies. J. Tumor Market Oncology 7, 90, 1992.
  • Morgan LR, Hooper CL, Benes R. Topical use of 4, 4-dihydroxybenzophenome-2, 4-dinitrophenylhydrazone (A-007) in advanced cutaneous metastasis from breast cancer. European Cancer Soc. XVII Congress, Lyon, France, Nov. 1992.
  • Gottlieb AA, Fanner JL, Benes E, et al. Augmentation of antigen induced interleukin-2 receptor expression and gamma interferon production by IMREG-1, a leukocyte-derived immunomodulator. Clinical Immunology, 357-361, 1987.
  • Lyons GD, Benes EN. Laser surgery and immunotherapy in the management of laryngeal papilloma. The Laryngoscope Vol. LXXXVIII, No. 10, pp. 1586-1588, October 1978.
  • Krementz ET, Mansell PWA, Homung MO, Samuels MS, Sutherland CA, Benes EN. The use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes. Cancer Vol. 33, No. 2, February 1974.
  • Krementz ET, Goodwin DP, Samuels MS, Homung MO, Benes EN. Immunologic approaches in the management of malignant melanoma. Melanoma and skin cancer (pp. 473-495) V.C.N. Bright, Govt. Printer, New S. Wales, 1972.
  • Krementz ET, Samuels MS, Wallace JH, Benes E. Clinical experiences in immunotherapy of cancer. Surgery, Gynecology, and Obstetrics, Vol. 133 pp. 209-217, August 1971.
  • Jamieson CW, Russin D, Benes EN, DeWitt CW, Wallace JH. Growth inhibitory effects of non-immune lymphocytes on tumor cells in vitro in the absence of mitogenic agents. Nature, Vol. 222, No. 5290, pp. 284-285, April 19, 1969.
  • Benes E, Gottlieb AA. Effect of IMREG-I on intracellular calcium levels of human peripheral blood mononuclear cells. FASEB, (abst.) 4:7, June 1990.
  • Thangaraj K, Morgan LR, Benes E, Jursic BS, Stevens ED, Sivanandham M. Aromatic and heteroaromatic-2, 4-dinitrophenvlhydrazones as anticancer agents. Amer. Chem. Soc. Abst, Chicago, 1993.
  • Gottlieb AA, Sizemore RC, Montgomery AH, Benes EN. IMREG-I, Augments II,-2 receptor expression on CD4+ lymphocytes of normals and patients with ARC. International Conference of AIDS (abst.) Book 1, pp. 232, 1988.

DEKK-TEC News

Fast Fact Product Reviews

One of our products – isophosphoramide mustard (IPM) – that was licensed to ZIOPHARM Oncology, Inc. – now known as ‘Palifosfamide’ is moving nicely in Phase III trials. DEKK-TEC was awarded a US patent 7,678,778 for drug composition of matter and the concept. A recent presentation, which received a ‘PICASSO’ award, can be viewed by [...]

More News >>